Kanion Pharmaceutical To Set Up Production Facility In Zhongshan
This article was originally published in PharmAsia News
Kanion Pharmaceutical Co. Ltd. has signed an agreement with Zhongshan city in Guangdong province to set up an anti-tumor drug production base and R&D center. It has committed an initial investment of 280 million yuan. The annual production value is projected to reach 2 billion yuan when the facility is in full operation. The Modern Chinese Medicine Park of South China promises to provide support in terms of land, location, R&D, tax relief, registration and other industry services. Kanion is a top-50 TCM enterprise and its key product, Guizhi Fuling soft gel capsule, has received approval for a Phase II clinical trial in the U.S. (Click here for more - Chinese Language)
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.